Complete response with pembrolizumab in recurrent squamous cell carcinoma of the oral tongue: A case report.
Oral Oncol
; 147: 106597, 2023 Dec.
Article
en En
| MEDLINE
| ID: mdl-37857230
ABSTRACT
Immunotherapies such as immune checkpoint inhibitors have shown promising results in solid tumors associated with BRCA2, but there are no consistent predictors for who will respond to immunotherapy. More research is needed on the impact of this mutation in head and neck squamous cell carcinomas, particularly for recurrent/metastatic tumors. We report a case of stage IV oral squamous cell carcinoma associated with BRCA2 mutation that achieved complete remission with pembrolizumab treatment for relapsed disease.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias de la Boca
/
Carcinoma de Células Escamosas
/
Neoplasias de Cabeza y Cuello
Límite:
Humans
Idioma:
En
Revista:
Oral Oncol
Asunto de la revista:
NEOPLASIAS
Año:
2023
Tipo del documento:
Article